Skip to content

Comparison of preoperatively using insulin injection or oral hypoglycemic drug in patients undergoing total hip arthroplasty or total knee arthroplasty with diabetes mellitus

Comparison of preoperatively using insulin injection or oral hypoglycemic drug in patients undergoing total hip arthroplasty or total knee arthroplasty with diabetes mellitus

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16008228
Enrollment
Unknown
Registered
2016-04-06
Start date
2016-04-07
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-staged joint diseases

Interventions

A:insulin injection
B:oral hypoglycemic drug

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients receiving total hip arthroplasty/total knee arthroplasty for end-staged joint diseases; 2. Age from 40-80 years with no limitation of gender; 3. the patients with type 2 diabetes; 4. Patients who volunteered to participate in clinical trials and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients combined with acute trauma, tumor, severe osteoporosis, other autoimmune diseases and severe muscle contracture deformity around hip/knee; 2. Previous history of neuro-vascular injury, vasculitis and diabetic foot etc; 3. Related thrombosis history, such as pulmonary embolism, thrombosis and deep vein thrombosis in recent three months; 4. Coagulation disorders, bleeding tendency or intraoperative active bleeding; 5. Clear history of iron metabolism disorders; 6. Sever comorbidities in brain cardiovascular system, liver (ALT or AST >2 high limitation of normal value), kidney (BUN >1.5 high limitation of normal value or Cr> 1.5 high limitation of normal value), endocrine, nerve, hematopoietic system or consciousness disorders; 7. Pregnancy or breast-feeding; 8. Allergy to the test drug and human serum albumin, severe allergies, drug or alcohol depedence; 9. Participate in other clinical trials in recent three months; 10. The surgeons believe the patients not suitable for this clinical trial.

Design outcomes

Primary

MeasureTime frame
fasting blood-glucose;postprandial blood sugar;

Secondary

MeasureTime frame
Complications related to diabetes;range of motion;KSS;WOMAC;wound healing;SF-12;hospital stay;ambulation time;limb swelling;

Countries

China

Contacts

Public ContactZongke Zhou

West China Hospital, Sichuan University

zongke@126.com+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026